tradingkey.logo
tradingkey.logo

Evaxion Biotech A/S

EVAX
View Detailed Chart
3.560USD
-0.030-0.84%
Market hours ETQuotes delayed by 15 min
29.69MMarket Cap
LossP/E TTM

Evaxion Biotech A/S

3.560
-0.030-0.84%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.84%

5 Days

-8.95%

1 Month

+12.66%

6 Months

-6.32%

Year to Date

-25.37%

1 Year

+102.27%

View Detailed Chart

TradingKey Stock Score of Evaxion Biotech A/S

Currency: USD Updated: 2026-03-27

Key Insights

Evaxion Biotech A/S's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 166 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.25.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Evaxion Biotech A/S's Score

Industry at a Glance

Industry Ranking
166 / 391
Overall Ranking
297 / 4542
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Evaxion Biotech A/S Highlights

StrengthsRisks
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 10212.33% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.53M.
Fairly Valued
The company’s latest PE is -2.93, at a medium 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.

Analyst Rating

Based on 4 analysts
Buy
Current Rating
11.250
Target Price
+213.37%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Evaxion Biotech A/S News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Evaxion Biotech A/S Info

Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Ticker SymbolEVAX
CompanyEvaxion Biotech A/S
CEO
Websitehttps://evaxion.ai/
KeyAI